GlassScriptPhysician profile
Nimal H Patel
NPI 1417292392
$10,795.21
in general payments reported to CMS, 2019-2025
33 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $353 · 2021: $1,167 · 2022: $1,893 · 2023: $2,138 · 2024: $2,942 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,088 · Consulting Fee: $50.00 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,087.85 |
| Consulting Fee | $50.00 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,344.75 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $1,029.74 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $1,000.09 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $947.72 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $604.20 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $501.46 | 2020-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $329.64 | 2019-2023 | |
| Genzyme Corporation | $317.84 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.65 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $293.29 | 2020-2025 | Linzess |
| Pfizer INC. | $203.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.58 | 2022-2025 | Dupixent |
| Axonics, INC. | $193.99 | 2023-2024 | Axonics |
| Ardelyx, INC. | $171.62 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $168.32 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167.68 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $156.38 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $132.58 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $126.55 | 2022-2024 | Dificid, Zinplava, Zerbaxa |
| Amgen INC. | $93.44 | 2022-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $92.04 | 2020-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $87.22 | 2022-2023 | |
| Boston Scientific Corporation | $82.50 | 2022-2025 | Cre Pro, Axonics |
| Medtronic, INC. | $50.00 | 2023 | Straightshot |
| Vivus LLC | $39.05 | 2024-2025 | Pancreaze |
| Alnylam Pharmaceuticals INC. | $30.87 | 2025 | Givlaari |
| Fujifilm Healthcare Americas Corporation | $23.71 | 2023 | Fujifilm |
| Enterra Medical, INC. | $23.48 | 2023 | |
| Organon LLC | $17.44 | 2024 | |
| Capsovision, INC. | $17.03 | 2023 | Capsocam Plus |
| Daiichi Sankyo INC. | $16.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Ethicon US, LLC | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.